Drugmaker Novo Nordisk on Tuesday reported the results of a new study that tracked more than 17,000 adults over the age of 45 who were overweight or obese and had cardiovascular disease but no history of diabetes.
Wednesday, Dr. Céline Gounder, a CBS News medical contributor and editor-at-large for public health at KFF Health News, said these results were better than expected.
"A 20% reduction in heart attacks and stroke from a weight loss medication — we've never seen that before with any approved weight loss medication," she said.Wegovy, a brand-name formulation of the GLP-1 receptor agonist semaglutide, received approval to treat adult obesity in 2021. An earlyThis latest study shows semaglutide can reduce patients' risks of experiencing cardiac events, which are more common in overweight and obese individuals.
Some insurers are paying tens of millions of dollars per month for semaglutide as more Americans are prescribed the medications, the Wall Street Journal
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Read more »
Weight-Loss Drug Wegovy Cuts Stroke, Heart-Attack Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Read more »
Novo Nordisk weight loss drug Wegovy cuts heart disease risk by 20%, trial showsResults of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
Read more »
Wegovy drug reduces cardiovascular risks by 20%, says drugmakerA new study by drugmaker Novo Nordisk reveals that the weight-loss drug Wegovy has significantly reduced the risk of heart attack, stroke, and cardiovascular death in overweight adults with cardiovascular disease.
Read more »
Wegovy Reduces Risk of Heart Attack and Stroke in Major Cardiovascular TrialA major clinical trial has shown that the weight loss drug Wegovy can reduce the risk of heart attack, stroke, or heart disease-related death by 20% in people with cardiovascular disease, marking the first time a weight loss drug has demonstrated such protective effects.
Read more »